Balyasny Asset Management
ABOS icon

Balyasny Asset Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Balyasny Asset Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-63,949
Closed -$259K – 2506
2024
Q1 		$259K Buy
63,949
+43,371
+211% +$163K ﹤0.01% 2314
2023
Q4 		$79K Buy
+20,578
New +$61.1K ﹤0.01% 2395
2023
Q3 		– Sell
-30,222
Closed -$145K – 2200
2023
Q2 		$145K Buy
+30,222
New +$145K ﹤0.01% 2097

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Balyasny Asset Management's ABOS Position: Q2 2024 in Review

Balyasny Asset Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2024, closing a stake of 63,949 shares — an estimated $259K sold.

Balyasny Asset Management first reported a position in ABOS in Q2 2023 and held it in 3 quarters. The position peaked at $259K in Q1 2024. 81 funds tracked by Wall St. Rank hold ABOS as of Q2 2024.

  • Balyasny Asset Management reported no remaining Acumen Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 63,949 Acumen Pharmaceuticals shares in Q2 2024, an estimated $259K.
  • Balyasny Asset Management first reported a position in Acumen Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Balyasny Asset Management's Acumen Pharmaceuticals position peaked at $259K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.